Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge

Executive Summary

At ACR: Janssen reported data that show Celltrion’s Remicade biosimilar is not quite the same, but positive sirukumab results may not boost the Janssen and GSK biologic’s market prospects. Meanwhile, Corbus surged on mid-stage resunab results in systemic sclerosis, Janssen shared Phase II gesulkumab psoriasis results, Genentech eyes a new Actemra indication, and Xencor rose on interim Phase II data.

Advertisement

Related Content

NOR-SWITCH Results ‘Concerning’ In Crohn’s Disease, Says Janssen
Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss
Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study
PIPELINE WATCH: 19 Approvals, Nine Filings And One Launch
Clever Marketing Needed To Position J&J's New Psoriasis Drug Ahead Of Cheaper Options
Case Studies: How Three Public Companies Financed R&D In A Tough Market
Too Little, Too Late For GSK/Janssen's Sirukumab in RA?
With Baricitinib, Lilly Hopes To Succeed Where Pfizer Has Struggled
Video Interview: Corbus Sees 2016 As Pivotal Year
A test for anti-TNF non-responders? Few alternative RA therapies available

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097681

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel